Nutrigenomics, obesity and public health;Nutrigenómica, obesidad y salud pública

Revista Espanola de Salud Publica

Volumn 81, Issue 5, 2007, Pages 475-487

  Rodríguez, Manuela Belén Silveira ^a   Muñoz, Lourdes Martínez Piñeiro ^a   Casieri, Raffaele Carraro ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cardiovascular diseases; Epigenetic; Epistasis; Genes; Genetic; Genomics; Nutrigenomics; Nutrition; Obesity; Public health

Indexed keywords

EID: 39149111908     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: 10.1590/s1135-57272007000500005     Document Type: Review

References (84)

1. Rubio MA, Salas-Salvadó J, Barbany M, et al. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Rev Esp Obes. 2007; 5 (3): 135-75.
2. Calle EE, Thun MJ, Petrelli JM, et al. Body mass index in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341: 1097-105.
3. Aranceta-Bartrina J, Serra-Majem Ll, Foz-Sala M, et al. Prevalencia de obesidad en España. Med Clin (Barc). 2005;125(12):460-6.
4. Serra-Majem Ll, Ribas Barba L, Aranceta Bartrina J, et al. Obesidad infantil y juvenil en España. Resultados del Estudio Enkid (1998-2000). Med Clin(Barc). 2003; 121: 725-32.
5. Aranceta J, Pérez Rodrigo C, Muñoz M. Perfil nutricional de los ancianos institucionalizados en España. En: Muñoz M, Aranceta J, Guijarro JL (eds). Libro blanco de la alimentación del anciano en España. Madrid: Panamericana; 2004.
6. Rankinen T, Zuberi A, Chagnon YC, et al. The Human Obesity Gene Map: The 2005 update. Obesity 2006; 14 (4): 529-644.
7. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007. 316: 889-94,.
8. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med. 2005; 56: 303-20.
9. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C->T polymorphism and risk of coronary heart disease: A Meta-analysis. JAMA. 2002; 288:2023.
10. Kohara K, Fujisawa M, Ando F, et al. MTHFR Gene Polymorphism as a Risk Factor for Silent Brain Infarcts and White Matter Lesions in the Japanese General Population: The NILS-LSA Study. Stroke. 2003; 34:1130.
11. Tsai, AW, Cushman, M, Tsai, MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 2003; 72:192.
12. Bezemer, ID, Doggen, CJ, Vos, HL, Rosendaal, FR. No Association Between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results From the MEGA Study. Arch Intern Med. 2007; 167:497.
13. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999; 340:9.
14. Altomare I, Adler A, Aledort LM. The 5, 10 methylenetetrahydrofolate reductase C677T mutation and risk of fetal loss: a case series and review of the literature. Thromb J. 2007, 5:17 (epub 17-10-2007).
15. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ. 1998; 316:894-8.
16. Wald, DS, Bishop, L, Wald, NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med. 2001; 161:695.
17. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006; 47:1108.
18. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006; 296:2720.
19. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood. 2007; 109:139.
20. Ordovas JM. Gene interactions with diet influence the risk of cardiovascular disease. Am J Clin Nutr. 2006; 83(suppl): 443S-6S.
21. Zeisel HS. Nutrigenomics and metabolomics will change clinical nutrition and public health practice: insights from studies on dietary requierements for choline, Am J Clin Nutr. 2007; 86; 542-8.
22. Sessler AM, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. J Nutr .1998;128:923-6.
23. Fernández ML, West KL. Mechanisms by which Dietary Fatty Acids Modulate Plasma Lipids. J Nutr. 2005; 135:2075-8.
24. Fernández-Quintela A, Churruca I, Puy Portillo M. The role of dietary fat in adipose tissue metabolism. Pub Health Nutr. 2007; 10 (10A): 1126-31.
25. Clarke SD, Gasperikova D, Nelson C, et al. Fatty acid regulation of gene expression: a genomic explanation for the benefits of the mediterranean diet. Ann N Y Acad Sci 2002;967:283-98.
26. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res. 2001;40(4):283-98.
27. House RL, Cassady JP, Eisen EJ, et al. Conjugated linoleic acid evokes de-lipidation through the regulation of genes controlling lipid metabolism in adipose and liver tissue. Obes Rev. 2005;6(3):247-58.
28. Tricon S, Burdge GC, Kew S, et al. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. Am J Clin Nutr. 2004;80(3):614-20.
29. Tricon S, Burdge GC, Jones EL, et al. Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men. Am J Clin Nutr. 2006;83(4):744-53.
30. Terpstra AH. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. Am J Clin Nutr. 2004;79(3):352-61.
31. Choi Y, Kim YC, Han YB, et al. The trans-10,cis-12 isomer of conjugated linoleic acid downregulates stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. J Nutr. 2000;130(8):1920-4.
32. Park Y, Storkson JM, Ntambi JM, et al. Inhibition of hepatic stearoyl-CoA desaturase activity by trans-10, cis-12 conjugated linoleic acid and its derivatives. Biochim Biophys Acta 2000;1486(2-3):285-92.
33. Park Y, Storkson JM, Albright KJ, et al. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999 Mar;34(3):235-41.
34. Brown JM, Boysen MS, Chung S, et al. Conjugated linoleic acid (CLA) induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines. J Biol Chem. 2004; 279: 26735-47.
35. Riserus U, Smedman A, Basu S, Vessby B. Metabolic effects of conjugated linoleic acid in humans: the Swedish experience. Am J Clin Nutr. 2004; 79: 1146S-1148S.
36. Riserus U, Vessby B, Arner P, Zethelius B. Supplementation with trans10cis12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetologia. 2004;47(6):1016-9.
37. Moloney F, Yeow TP, Mullen A, et al. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2004; 80(4):887-95.
38. Moloney F, Toomey S, Noone E, et al. Antidiabetic Effects of cis-9, trans-11-Conjugated Linoleic Acid May Be Mediated via Anti-Inflammatory Effects in White Adipose Tissue. Diabetes. 2007; 56:574-582.
39. Poirier H, Shapiro JS, Kim RJ, Lazar MA. Nutritional Supplementation With trans-10, cis-12-Conjugated Linoleic Acid Induces Inflammation of White Adipose Tissue. Diabetes. 2006; 55: 1634-41.
40. Silveira MB, Carraro R, Monereo S, Tébar J. Conjugated linoleic acid (CLA) and obesity. Pub Health Nutr. 2007; 10 (10A): 1181-6.
41. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet. 1999; 23:314-8.
42. L.H. Lumey, Decreased birthweights in infants after maternal in utero exposure to the Dutch famine of 1944-1945. Paediatr Perinat Epidemiol. 1992; 6: 240-53.
43. Barker DJ. Fetal growth and adult disease. Br J Obstet Gynaecol. 1992;99:275-6.
44. Hales CN, Barker DJ.The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5-20.
45. Barker DJ. The fetal origins of diseases of old age. Eur J Clin Nutr. 1992;46(suppl):S3-9.
46. Osmond C, Barker DJ, Winter PD, et al. Early growth and death from cardiovascular disease in women. BMJ. 1993;307:1519-24.
47. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ. 1993;306:422-6.
48. Rich-Edwards J, Stampfer M, Manson J, et al. Birthweight, breastfeeding, and the risk of coronary heart disease in the Nurses' Health Study. Am J Epidemiol. 1995;141:S78.
49. Frankel S, Elwood P, Sweetnam P, et al. Birthweight, adult risk factors and incident coronary heart disease: the Caerphilly Study. Public Health. 1996;110:139-43.
50. Leon DA, Koupilova I, Lithell HO, et al. Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50 year old Swedish men. BMJ. 1996;312:401-6.
51. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. N Engl J Med. 1976;295:349-53.
52. Gluckman PD, Hanson MA. Living with the past: evolution, development and patterns of disease. Science. 2004; 305:1773-1776.
53. Hales CN, Barker DJ, Clark PM, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303:1019-22.
54. Phipps K, Barker DJ, Hales CN, et al. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993;36:225-8.
55. Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37:150-4.
56. Vickers MH, Breier BH, Cutfield WS, et al. Fetal origins of hyperphagia, obesity and hypertension and its postnatal amplification by hypercaloric nutrition. Am J Physiol. 2000; 279:E83-E87.
57. Gluckman PD, Hanson MA, Spencer HG. Predictive adaptive responses and human evolution. Trends Ecol Evol. 2005; 20 (10): 527-33.
58. Rickard IJ, Lummaa V. The Predictive Adaptive Response and metabolic syndrome: Challenges for the hypothesis. Trends Endocrinol Metab. 2007; 18 (3): 94-9.
59. Pinto S, Roseberry AG, Liu H, et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science. 2004; 304:110 -115.
60. Bouret SG, Draper SJ, Simerly RB. Trophic action of leptin on hypothalamic neurons that regulate feeding. Science. 2004; 304:108 -110.
61. Islam M, Sjöholm Å, Emilsson V. Fetal pancreatic islets express functional leptin receptors and leptin stimulates proliferation of fetal islet cells. Int J Obes Relat Metab Disord. 2000, 24:1246-53.
62. Vickers MH, Gluckman PD, Coveny AH, et al. Neonatal Leptin Treatment Reverses Developmental Programming. Endocrinology. 2005;146:4211-6.
63. Miralles O, Sánchez J, Palou A, Picó C. A Physiological Role of Breast Milk Leptin in Body Weight Control in Developing Infants. Obesity. 2006; 14:-1371-77.
64. Uysal FK, Onal EE, Aral YZ, et al. Breast milk leptin: its relationship to maternal and infant adiposity. Clin Nutr. 2002;21:157-60.
65. Ucar B, Kirel B, Bor O, et al. Breast milk leptin concentrations in initial and terminal milk samples: relationships to maternal and infant plasma leptin concentrations, adiposity, serum glucose, insulin, lipid and lipoprotein levels. J Pediatr Endocrinol Metab. 2000;13:149-56.
66. Kramer MS. Do breast-feeding and delayed introduction of solid foods protect against subsequent obesity? J Pediatr. 1981;98:883-7.
67. von Kries R, Koletzko B, Sauerwald T, et al. Breast feeding and obesity: cross sectional study. BMJ. 1999;319:147-50.
68. Armstrong J, Reilly JJ. Breastfeeding and lowering the risk of childhood obesity. Lancet. 2002;359:2003-4.
69. Hediger ML, Overpeck MD, Kuczmarski RJ, Ruan WJ. Association between infant breastfeeding and overweight in young children. JAMA. 2001;285:2453-60.
70. Li L, Parsons TJ, Power C. Breast feeding and obesity in childhood: cross sectional study. BMJ. 2003;327:904-5.
71. Kaati G, Bygren LO, Edvinssons S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet. 2002; 10:682-8.
72. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulinlike growth factors in embryonic and postnatal growth. Cell. 1993; 75:73-82.
73. Constancia M, Hemberger M, Hughes J, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002; 417: 945-8.
74. Pietiläinen K, Rissanen A, Laamanen M, et al. Growth Patterns in Young Adult Monozygotic Twin Pairs Discordant and Concordant for Obesity. Twin Res. 2005; 7 (5): 421-429.
75. Kaiser J. Developmental biology. Endocrine disrupters trigger fertility problems in multiple generations. Science. 2005; 308:1391-2.
76. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes Mutat Res. 2006; 600: 46-57.
77. Pembrey ME. Time to take epigenetic inheritance seriously. Eur J Hum Genet. 2002; 10:669-71.
78. Yu YH, Zhu H. Chronological changes in metabolism and functions of cultured adipocytes: a hypothesis for cell aging in mature adipocytes. AJP-Endo 2004; 286:402-10.
79. Silveira MB, Carraro R, Gómez-Pan A. El aparato digestivo como órgano endocrino: nuevas perspectivas en el tratamiento de la obesidad. Med Clín (Barc). 2006; 127: 300-5.
80. Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Aging Res Rev. 2006; 5: 144-164.
81. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta. 2002;1585: 202-212.
82. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol. 1999; 84: 3J-10J.
83. Recasens M, Ricart W, Fernandez-Real JM. Obesidad e inflamación. Rev Med Univ Navarra 2004;48(2):49-54.
84. Ruiz-Torres A, Lozano R, Melón J, et al. On how insulin may influence ageing and become atherogenic throughout IGF-1 receptor pathway: In vitro studies with human vascular smooth muscle cells. Gerontology. 2005; 51:225-230.